Asset
Cyclophosphamide
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02876510 | phase1 | completed | 2017-06-30 | 2021-09-22 | Immatics US, Inc. | ACTolog in Patients With Solid Cancers |
| NCT01265901 | phase3 | completed | 2010-12-01 | 2015-07-01 | Immatics Biotechnologies GmbH | IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma |
| NCT01403285 | phase1 | terminated | 2011-08-01 | 2014-04-01 | Immatics Biotechnologies GmbH | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma |
FDA applications (0)
This company has no applications containing this asset.